

| Research Ethics Committee Reference Number | Integrated Research Application System (IRAS) number | Name of Trial | Target number of patients agreed? | Min. number of patients agreed | Max. number of patients agreed | Target date to recruit patients agreed? | Date agreed to recruit target number of patients | Total number of patients recruited at the agreed target date | Total number of study participants recruited | Date that the trial closed to recruitment | Reason for closure of trial | Comments |
|--------------------------------------------|------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|--------------------------------|--------------------------------|-----------------------------------------|--------------------------------------------------|--------------------------------------------------------------|----------------------------------------------|-------------------------------------------|-----------------------------|--------------------------------------------------------------------------------------------------------------|
| 14/SC/1161 | 155743 | Prospective, single-arm, multi-centre, observational registry to further validate safety and efficacy of the ultimaster DES in real-world patients. | Number Agreed | 30 | 30 | Not Available / Not Agreed | | | 21 | 17/04/2018 | Recruitment Finished | Global competition. |
| 16/EM/0133 | 184873 | A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis | Number Agreed | 5 | 5 | Date Agreed | 25/07/2017 | 0 | 1 | 31/05/2018 | Recruitment Finished | Three additional patients screen failed prior to randomisation. Lack of patients meeting inclusion criteria. |
| 17/EM/0075 | 222172 | Evaluating the tolerance, compliance and acceptability of a nutritionally complete, high energy, high protein, enteral feed in adults ? a pilot study | Range Agreed | 5 | 14 | Date Agreed | 01/09/2017 | 7 | 9 | 31/05/2018 | Recruitment Finished | Target met. |
| 16/LO/0553 | 194625 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER LONG-TERM SAFETY AND TOLERABILITY STUDY OF ETC-1002 IN PATIENTS WITH HYPERLIPIDEMIA AT HIGH CARDIOVASCULAR RISK WHO ARE NOT ADEQUATELY CONTROLLED BY THEIR LIPID-MODIFYING THERAPY | Number Agreed | 8 | 8 | Not Available / Not Agreed | | | 8 | 18/04/2018 | Recruitment Finished | Target met. |
| 17/YH/0071 | 223653 | A MULTICENTER OPEN-LABEL EXTENSION (OLE) STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF BEMPEDOIC ACID (ETC-1002) 180 MG | Range Agreed | 3 | 5 | Not Available / Not Agreed | | | 3 | 23/03/2018 | Recruitment Finished | Target met. |

| Research Ethics Committee Reference Number | Integrated Research Application System (IRAS) number | Name of Trial | Target number of patients agreed? | Min. number of patients agreed | Max. number of patients agreed | Target date to recruit patients agreed? | Date agreed to recruit target number of patients | Total number of patients recruited at the agreed target date | Total number of study participants recruited | Date that the trial closed to recruitment | Reason for closure of trial | Comments |
|--------------------------------------------|------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|--------------------------------|--------------------------------|-----------------------------------------|--------------------------------------------------|--------------------------------------------------------------|----------------------------------------------|-------------------------------------------|-----------------------------|--------------------------------------------------------------|
| 15/SW/0194 | 185459 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase 3 study to investigate the efficacy of finerenone on the progression of deterioration of kidney function in patients with type 2 diabetes mellitus and the | Number Agreed | 12 | 12 | Date Agreed | 14/09/2017 | 6 | 8 | 08/06/2018 | Recruitment Finished | High number of patients failed screening tests post consent. |